Seminar

22 November 2017: Seminar on Biosimilars & Competition Law

22 November 2017: Seminar on Biosimilars & Competition Law

16.10.2017 EU law

On Wednesday 22 November 2017, Stibbe will organise a seminar on Biosimilars & Competition Law in Brussels. This seminar will be co-organized by competition lawyers from Stibbe and competition economists from CRA so as to cover both legal and economic angles relevant to this increasingly important field. 

Given the ever increasing economic significance of biologics in the pharmaceutical space – as well as signals from regulators that this field will come into focus shortly – it  is time to explore the implications of the competition rules for business behavior in this area. This includes a discussion of the following topics/questions: 

  • What can we expect from competition authorities in this space?
  • To what extent do the competition law principles developed for synthetic drugs apply to the biological space?
  • How does this play out in the context of life cycle management?  
  • What stance do authorities take in merger control cases involving biologics?
  • What about pricing strategies? Is there more reason for concern following cases like Aspen (EU) and Pfizer (UK)?

Our intention is to go beyond scratching the surface on these topics in order to provide guidance for pharmaceutical companies in an area which we feel is receiving insufficient attention in the competition law domain. 

For more information and to register, please send an email to: StibbeEvents@Stibbe.com.

A provisional program can be found below: 

  • 12:00 - 12:30: Registration
  • 12:30 - 12:45:  Introduction by chair - Stibbe/CRA
  • 12:45 - 13:15: Keynote speech by Paul Paul Csiszár, Director of "Basic Industries, Manufacturing and Agriculture", responsible for the Commission’s pharma unit
  • 13:15 - 13:45: Industry trends in biosimilars - Tim Wilsdon, CRA  
  • 13:45 - 14:30: Biologics in EU merger control: current status and likely issues in the future - Stibbe
  • 14:30 - 15:00: Break
  • 15:00 - 15:45: Competition law boundaries of life cycle management strategies: application to the biologics space - Stibbe
  • 15:45 - 16:30: Pricing practices & antitrust: law and economics - Raphaël De Coninck, CRA
  • 16:30 - 16: 45: Closing
  • 16:45 - 17:30: Drink

When: 22 November 2017 from 12.00 -17.30.

Where: Stibbe office: Central Plaza - Loksumstraat 25 Rue de Loxum - 1000 Brussels

stibbe_logo_background_01    logo - CRA

 

Team

Related news

13.02.2018 BE law
Du nouveau en matière de « plans et programmes » !

Articles - Dans ses conclusions du 25 janvier 2018 établies dans le cadre de deux demandes de décision préjudicielle formées par le Conseil d’Etat de Belgique, l’avocat général J. KOKOTT a considéré que le périmètre de remembrement urbain en Wallonie et le règlement régional d’urbanisme en Région de Bruxelles-Capitale sont des « plans et programmes ».

Read more

16.02.2018 EU law
Who is a consumer? The dynamic approach to the concept of 'consumer' under the Brussels I Regulation

Short Reads - On 25 January 2018, the European Court of Justice ("ECJ") rendered a preliminary ruling in a case between Austrian citizen Maximilian Schrems and online social network Facebook. The ruling is important for two reasons. First, the ECJ approved a dynamic approach to the concept of 'consumer' under the Brussels I Regulation. Secondly, the ECJ clarified that the special consumer forum can only be invoked by the specific consumer who is party to the contractual relationship with the professional trader.

Read more

01.02.2018 EU law
Participation d’entreprises liées aux marchés publics: qui assume la responsabilité ?

Articles - L’avocat général Campos Sanchez-Bordona a récemment déposé des conclusions intéressante dans le cadre de l’affaire nr. C-531/A6 dont la Cour de justice a été saisie. Selon l’avocat général, des soumissionnaires qui sont liés mais qui présentent chacun une offre séparée pour un marché public déterminé n’ont pas à informer le pouvoir adjudicateur des liens existant entre eux. Il ressort en outre des conclusions que le pouvoir adjudicateur n’est pas légalement tenu de vérifier de manière active la participation d’entreprises liées à un marché public.

Read more

Our website uses cookies: third party analytics cookies to best adapt our website to your needs & cookies to enable social media functionalities. For more information on the use of cookies, please check our Privacy and Cookie Policy. Please note that you can change your cookie opt-ins at any time via your browser settings.

Privacy and Cookie Policy